Preclinical Studies and Optimization of Specific Tumor Delivery for 741F8 sFv, an Anti-c-erbB-2 Single-Chain Species

References

• Adams G. P, McCartney J. E, Tai M-S., Oppermann H., Huston J. S, Stafford W. F, Bookman M. A, Fand I., Houston L. L, Weiner L. M. Highly specific in vivo, tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2, single-chain Fv. Cancer Res. 1993; 53: 4026–4034
   PubMed Web of Science ®Google Scholar
• Adams G. P, DeNardo S. J, Amin A., Kroger L. A, De-Nardo G. L, Hellstrom I., Hellstrom K. E. Comparison of the pharmacokinetics in mice and the biological activity of murine L6 and human-mouse chimeric ch-L6 antibody. Antibody, Immunoconj. Radiopharm. 1992; 5: 81–95
   Google Scholar
• Adams G. P, McCartney J. E, Wolf E. I, Eisenberg J., Tai M.-S., Huston J. S, Stafford I W.F., II, Bookman M. A, Houston L. L, Weiner L. M. Optimization of in vivo, tumor targeting with divalent forms of 741F8 single-chain Fv: Effects of dose escalation and repeated i.v. administration. Cancer Immunol. Immunother. 1995a, In press
   Google Scholar
• Adams G. P, Tai M.-S., Wolf E. J, Eisenberg J., Huston J. S, Bookman M. A, Moldofsky P., Stafford I W.F., II, Houston L. L, Weiner L. M. Enhanced tumor specificity with stably iodinated 741F8-2 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer. J. Nuc. Med. 1995b, In press
   Google Scholar
• Bindon C. I, Hale G., Bruggemann M., Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exper. Med. 1988; 168: 127–142
   PubMed Web of Science ®Google Scholar
• Blakey D. C, Valcaccia B. E, East S., Wright A. F, Boyle F. T, Springer C. J, Burke P. J, Melton R. G, Bag-Shawe K. D. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophy. 1993; 22: 1–8
   Google Scholar
• Brinkmann U., Pai L. H, Fitzgerald D. J, Willingham M., Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA 1991; 88: 8616–8620
   PubMed Web of Science ®Google Scholar
• Brinkmann U., Gallo M., Brinkmann E., Kunwar S., Pastan I. A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA 1993; 90: 547–551
   Google Scholar
• Brown L., Miller R. A, Horning S. J, Czerwinski D., Hart S. M, McElderry R., Basham T., Warnke R. A, Merigan T. C, Levy R. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with cc-interferon. Blood 1989; 72: 651–661
   Google Scholar
• Cheung N. K, Burch L., Kushner B. H, Munn D. H. Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: a phase II trial. Progress Clin. Biol. Res. 1991; 366: 395–400
   Google Scholar
• Clackson T., Hoogenboom H. R, Griffiths A. D, Winter G. Making antibody fragments using phage display libraries. Nature 1991; 352: 624–628
   PubMed Web of Science ®Google Scholar
• Colcher D., Minelli F. M., Roselli M., Muraro R., Simp-son-Milenic D., Schlom J. Radioimmu-nolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res. 1988; 48: 4597–4603
   PubMed Web of Science ®Google Scholar
• Colcher D., Bird R., Roselli M., Hardman K. D, Johnson S., Pope S., Dodd S. W, Pantoliano M. W, Milenic D. E, Schlom J. In vivo, tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst. 1990; 82: 1191–1197
   PubMed Web of Science ®Google Scholar
• DeNardo S. J, Peng J. S, DeNardo G. L, Mills S. M, Epstein A. L. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Nucl. Med. Biol. 1986; 13: 303–310
   Web of Science ®Google Scholar
• Dorai H., McCartney J. E, Hudziak R. M, Tai M.-S., Laminet A. A, Houston L. L, Huston J. S, Oppermann H. Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains. Bio/Technology 1994; 12: 890–897
   PubMedGoogle Scholar
• Fand I., Sharkey R. M., Grundy P., Goldenberg D. M. Localization by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer model. Int. J. Rad. Appl. Instr. - Part B, Nucl. Med. Biol. 1992; 19: 87–99
   PubMedGoogle Scholar
• Frankel A. E, Ring D. B, Tringale F., Hsieh-Ma S. T. Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J. Biol. Response Modifiers 1985; 4: 273–286
   PubMedGoogle Scholar
• Friedman P. N, McAndrew S. J, Gawlak S. L, Chace D., Trail P. A, Brown J. P, Siegall C. B. BR96 sFv-PE40, a potent cingle-chain immunotoxin that selectively kills carcinoma cells. Cancer Res. 1993; 53: 334–339
   PubMed Web of Science ®Google Scholar
• Fujimori K., Covell D. G, Fletcher J. E, Weinstein J. N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res. 1989; 49: 5656–5663
   PubMed Web of Science ®Google Scholar
• Gallinger S., Reilly R. M, Kirsh J. C, Odze R. D, Hay K., Polihronis J., Damani M. T, Shpitz B., Stern H. S. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res. 1993; 53: 271–278
   PubMed Web of Science ®Google Scholar
• George A. JT., Titus J. A, Jost C. R, Kurucz I., Perez P., Andrew S. M, Nicholls P. J, Huston J. S, Segal D. M. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule. J. Immunol. 1994; 152: 1802–1811
   Google Scholar
• George A. JT., Jamar F., Tai M.-S., Heelan B. T, Adams G. P, McCartney J. E, Houston L. L, Weiner L. W, Oppermann H., Peters A. M, Huston J. S. Radiometal labeling of recombinant proteins by a genetically engineered, minimal chelation site: coordination of technetium-99m by single-chain Fv antibody fusion proteins through a carboxyl-terminal cysteinyl peptide. Proc. Natl. Acad. Sci. USA . 1995, In press
   Google Scholar
• Handgretinger R., Baader P., Dopfer R., Klingebiel T., Reuland P., Treuner J., Reisfeld R. A, Nietham-Mer D. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol. Immunother. 1992; 35: 199–204
   PubMed Web of Science ®Google Scholar
• Herlyn D., Ross A. H, Iliopoulos D., Koprowski H. Induction of specific immunity to human colon carcinoma by anti-idiotypic antibodies to monoclonal antibody C017-1 A. Eur. J. Immunol. 1987; 17: 1649–1652
   PubMedGoogle Scholar
• The collected papers of Paul Ehrlich, B. Himmleweit. Pergamon Press, Elmsford, NY 1975
   Google Scholar
• Holton O. D, Black C D., Parker R. J, Covell D. G, Barbet J., Sieber S. M, Talley M. J, Weinstein J. N. Biodistribution of monoclonal IgGl, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies. J. Immunol. 1987; 139: 3041–3049, 3d.
   PubMed Web of Science ®Google Scholar
• Huse W. D, Sastry L., Iverson S. A, Kang A. S, Alting-Mees M., Burton D. R, Benkovic S. J, Lerner R. A. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989; 246: 1275–1281
   PubMed Web of Science ®Google Scholar
• Huston J. S, Levinson D., Mudgett-Hunter M., Tai M.-S., Novotny J., Margolies M. N, Ridge R. J, Bruccol-Eri R. E., Haber E., Crea R., Oppermann H. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced. Escherichia coli. Proc. Natl. Acad. Sci. USA 1988; 85: 5879–5883
   PubMed Web of Science ®Google Scholar
• Huston J. S., Mudgett-Hunter M., Tai M.-S., McCartney J., Warren F., Haber E., Oppermann H. Protein engineering of single-chain Fv analogues and fusion proteins. Meth. Enzymol. 1991; 203: 46–88
   PubMed Web of Science ®Google Scholar
• Molecular Design and Modeling: Concepts and Applications, J. J. Langone. Academic Press, San Diego, Part B
   Google Scholar
• Huston J. S, McCartney J. E, Tai M.-S., Mottola-Hart-Shorn C, Jin D., Warren F., Keck P., Oppermann H. Medical applications of single-chain antibodies. Intern. Rev. Immunol. 1993a; 10: 195–217
   PubMedGoogle Scholar
• Huston J. S, Tai M.-S., McCartney J., Keck P., Oppermann H. Antigen recognition and targeted delivery by the single-chain Fv. Cell Biophysics 1993b; 22: 189–224
   Google Scholar
• Huston J. S, Adams G. P, McCartney J. E, Tai M.-S., Oppermann H., Liu S., Stafford I W.F., II, Bookman M. A, Fand I., Apell G., Laminet A, Houston L. L, Weiner L. M. Tumor targeting in a tumor xenograft model with the (sFv')2 divalent form of anti-c-erbB-2, single-chain Fv. Cell Biophysics 1994; 24/25: 249–257
   Google Scholar
• Huston J. S, George A. JT., Tai M.-S., McCartney J. E, Jin D., Segal D. M, Oppermann H. Single-chain Fv design and production by preparative folding. Antibody Engineering2nd edition, C. Borre-Baeck. Oxford University Press, New York and Oxford 1995; 185–225
   Google Scholar
• Hylarides M. D, Wilbur D. S, Reed M. W, Hadley S. W, Schroeder J. R, Grant L. M. Preparation and in vivo, evaluation of an N-(p-[125I]Iodophenethyl) maleimide-antibody conjugate. Bioconjugate Client 1991; 2: 435–440
   Google Scholar
• Jain R. K. Physiological resistance to the treatment of solid tumors. Fourth Annual JBC International Conference on Antibody Engineering 1993; 4: 87–105
   Google Scholar
• Junghans R. P, Waldmann T. A., Landolfi N. F, Avdalovic N. M, Schneider W. P, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990; 50: 1495–502
   PubMed Web of Science ®Google Scholar
• Juweid M., Neumann R., Paik C, Perez-Bacete M. J, Sato J., van Osdol W., Weinstein J. N. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992; 52: 5144–5153
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Zasady K. R, Francis I. R, Milik A. W, Ross C. W, Moon S. D, Crawford S. M, Burgess J. M, Petry N. A, Butchko G. M, et al. Radioimmu-notherapy of B-cell lymphoma with 131I-anti-Bl (anti-CD20) antibody. New Eng. J. Med. 1993; 329: 459–65
   PubMed Web of Science ®Google Scholar
• Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497
   PubMed Web of Science ®Google Scholar
• Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• LoBuglio A. F, Wheeler R. H, Trang J., Haynes A., Rogers K., Harvey E. B, Sun L., Ghrayeb J., Khaz-Aeli M. B. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc. Natl. Acad. Sci. USA 1989; 86: 4220–4224
   PubMed Web of Science ®Google Scholar
• LoBuglio A. F, Saleh M. N, Lee J., Khazaeli M. B, Car-Rano R., Holden H., Wheeler R. H. Phase I trial of multiple large doses of murine monoclonal antibody C017-1A. I. Clinical aspects. J. Natl. Cancer Inst. 1988; 80: 932–936
   PubMed Web of Science ®Google Scholar
• Lowder J. N, Meeker T. C., Campbell M., Garcia C. F, Gralow J., Miller R. A, Warnke R., Levy R. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood 1987; 69: 199–210
   PubMed Web of Science ®Google Scholar
• Marks J. D, Hoogenboom H. R, Bonnert T. P, McCaf-Ferty J., Griffiths A. D, Winter G. Bypassing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 1991; 222: 581–97
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents. J. Steroid Biochem. Mol. Biol. 1990; 37: 889–892
   Google Scholar
• Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Monographs - NCI 1992; 13: 125–131
   Google Scholar
• Miller R. A, Maloney D. G, Warnke R., Levy R. Treatment of B-cell lymphoma with monoclonal antiidiotype antibody. Medical Intelligence 1982; 306: 517–522
   Google Scholar
• McCabe R. P, Peters L. C, Haspel M. V., Pomato N., Carrasquillo J. A, Hanna M. G., Jr. Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors. Cancer Res. 1988; 48: 4348–4353
   PubMed Web of Science ®Google Scholar
• McCartney J. E, Tai M.-S., Hudziak R. M, Adams G. P, Weiner L. M, Jin D., Stafford I W.F., II, Liu S., Bookman M. A, Laminet A. A, Fand I., Houston L. L, Oppermann H., Huston J. S. Engineering disulfide-linked single-chain Fv dimers [(sFv')2] with improved solution and targeting properties. Anti-dig-oxin 26–10 (sFv')2 and emii-c-erbB-2, 741F8 (sFv')2 made by protein folding and bonded through carboxyl-termi-nal cysteinyl peptides. Protein Engineering 1995; 8, In press
   Google Scholar
• Milenic D. E, Yokota T., Filpula D. R, Finkelman M. AJ., Dodd S. W, Wood J. F, Whitlow M., Snoy P., Schlom J. Construction, binding properties, metabolism, and targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991; 51: 6363–6371
   PubMed Web of Science ®Google Scholar
• Morrison S. L. Transfectomas provide novel chimeric antibodies. Science 1985; 229: 1202–1207
   PubMed Web of Science ®Google Scholar
• Press O. W, Eary J. F, Appelbaum F. R, Martin P. J, Badger C. C, Nelp W. B, Glenn S., Butchko G., Fisher D., Porter B., Matthews D. C, Fischer L. D, Bernstein I. D. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. New Eng. J. Med. 1993; 329: 1219–1224
   PubMed Web of Science ®Google Scholar
• Pressman D., Korngold L. The in vivo, localization of anti-Wagner osteogenic sarcoma antibodies. Cancer 1953; 6: 619–623
   PubMed Web of Science ®Google Scholar
• Pressman D., Day E. D, Blau M. The use of paired labeling in the determination of tumor-localizing antibodies. Cancer Res. 1957; 17: 845–850
   PubMed Web of Science ®Google Scholar
• Ring D., Clark B. R., Saxena A. Identity of BCA200 and c-erbB-2 indicated by reactivity of monoclonal antibodies with recombinant c-erbB-2. Mol. Immunol. 1991; 28: 915–917
   Google Scholar
• Savage P., So A., Spooner R. A, Epenetos A. A. A recombinant single chain antibody interleukin-2 fusion protein. Br. J. Cancer 1993; 67: 304–310
   Google Scholar
• Scheinberg D. A, Lovett D., Divgi C. R., Graham M. C, Berman E., Pentlow K., Feirt N., Finn R. D, Clark-Son B. D., Gee T. S, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol. 1991; 9: 478–490
   PubMed Web of Science ®Google Scholar
• Schier R., Marks J. D, Wolf E. J, Apell G., Wong C, McCartney J. E, Bookman M. A, Huston J. S, Houston L. L, Weiner L. M, Adams G. P. In vitro, and in vivo, characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995; 1, In press
   Google Scholar
• Schott M. E, Milenic D. E, Yokota T., Whitlow M., Wood J. F, Fordyce W. A, Cheng R. C, Schlom J. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res. 1992; 52: 6413–6417
   PubMedGoogle Scholar
• Sharkey R. M, Gold D. V, Aninipot R., Vagg R., Bal-Lance C, Newman E. S, Ostella F., Hansen H. J, Goldenberg D. M. Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens. Cancer Res. 1990; 50: 828s–834s
   Google Scholar
• Shaw D. R, Khazaeli M. B, LoBuglio A. F. Mouse/human chimeric antibodies to a tumor-associated antigen1, biologic activity of the four human IgG subclasses. J. Natl. Cancer Inst. 1988; 80: 1553–1559
   PubMedGoogle Scholar
• Springer C. J, Poon G. K, Sharma S. K, Bagshawe K. D. Identification of prodrug, active drug, and metabolites in an ADEPT clinical study. Cell Biophysics 1993; 22: 9–26
   PubMedGoogle Scholar
• Tai M. S, Mudgett-Hunter M., Levinson D., Wu G. M, Haber E., Oppermann H., Huston J. S. A Afunctional fusion protein containing Fc-binding fragment B of staphylococcal protein A amino terminal to antidigoxin single-chain Fv. Biochem. 1990; 29: 8024–8030
   PubMed Web of Science ®Google Scholar
• Trail P. A, Willner D., Lasch S. J, Henderson A. J, Hof-Stead S., Casazza A. M, Firestone R. A, Hellstrom 1., Hellstrom K. E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261: 212–215
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S., Cordon-Cardo C, Carswell E., Mintzer D., Dantis L., Duteau C, Templeton M. A, Oettgen H. F, Old L. J, Houghton A. N. Phase I trial of a mouse monoclonal antibody against GD3 ganglio-side in patients with melanoma: induction of inflammatory responses at tumor sites. J. Clin. Oncol. 1988; 6: 1636–1648
   PubMed Web of Science ®Google Scholar
• Vitetta E. S, Stone M., Amlot P., Fay J., May R., Till M., Newman J., Clark P., Collins R., Cunningham D., et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991; 51: 4052–4058
   PubMed Web of Science ®Google Scholar
• Weiner L. M, Harvey E., Padavic-Shaller K., Willson J. K, Walsh C, LaCreta F., Khazaeli M. B, Kirkwood J. M., Haller D. G. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17–1A therapy in pancreatic carcinoma. J. Immunotherapy 1993; 13: 110–116
   Web of Science ®Google Scholar
• Weiner L. M, Houston L. L, Huston J. S, McCartney J., Tai M.-S., Appel G., Stafford I W.F., II, Bookman M. A, Gallo J., Adams G. P. Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Targeting 1995; 1: 51–60
   Google Scholar
• Weiner L. M, O'Dwyer P. J, Kitson J., Comis R. L, Fran-Kel A. E., Bauer R. J, Konrad M. S, Groves E. S. A phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res. 1989; 49: 4062–4067
   PubMed Web of Science ®Google Scholar
• Weiner L. M, Moldofsky P. J, Gatenby R. A, O'Dwyer J., O'Brian J., Litwin S., Comis R. L. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and murine monoclonal antibody C017–1A in advanced colorectal carcinoma. Cancer Res. 1988; 48: 2568–2573
   PubMed Web of Science ®Google Scholar
• Wels W., Harwerth I. M, Mueller M., Groner B., Hynes N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 1992; 52: 6310–6317
   PubMed Web of Science ®Google Scholar
• Wolf E. A, Schreiber G. J, Cosand W. L, Raff H. V. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice. Cancer Res. 1993; 53: 2560–2565
   Google Scholar
• Yokota T., Milenic D. E, Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992; 52: 3402–3408
   PubMed Web of Science ®Google Scholar
• Yokota T., Milenic D. E, Whitlow M., Wood J. F, Hubert S. L, Schlom J. Microautoradiograph-ic analysis of the normal organ distribution of radioiod-inated single-chain Fv and other immunoglobulin forms. Cancer Res. 1993; 53: 3776–3783
   PubMed Web of Science ®Google Scholar